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ABSTRACT
BACKGROUND: Although the prognosis of differentiated thyroid carcinoma (DTC) therapy 
is considered excellent over time, some cases have a poorer prognosis and evolve into death.
OBJECTIVE: This study aimed to estimate the 5-year specific survival and to identify prognosis 
factors in a cohort of DTC adult subjects. 
METHODS: Survival probability was estimated by Kaplan-Meier’s method in a retrospective 
hospital-based cohort study. Comparisons were made by log-rank test. Prognosis factors 
were identified using Cox risk modeling and crude and adjusted Hazard Ratio measures were 
obtained. Two models were estimated, considering age grouping of the 7th and 8th editions 
of TNM.
RESULTS: Specific 5-year survival in the cohort was 98.5% (95%CI: 94.2 – 97.5). Considering 
TNM 7th edition, the risk estimates were 9.88 (95%CI: 1.67 – 58.33) for age group ≥ 55 years, 
18.87 (95%CI: 7.38 – 48.29) for individuals with distant metastasis, 6.36 (95%CI: 2.26 – 17.91) for 
patients who underwent lymphadenectomy and 0.16 (95%CI: 0.06 – 0.43) for those who received 
radioiodine therapy. For TNM 8th edition, the risk estimates were 10.12 (95%CI: 2.05 – 50.09) for 
age group ≥ 55 years, 12.43 (95%CI: 4.58 – 33.77) for individuals with distant metastasis, 5.06 
(95%CI: 1.82 – 14.05) for patients who underwent lymphadenectomy and 0.19 (95%CI: 0.07 – 0.51) 
for those who received radioiodine therapy. 
CONCLUSIONS: This cohort had a very high survival over a 5-year period. The prognosis was 
negatively influenced by age, distant metastasis and lymphadenectomy, whereas radioiodine 
therapy was found to be protective.
DESCRIPTORS: Thyroid Neoplasms, epidemiology. Carcinoma. Survival Rate. Prognosis. Cohort 
Studies.
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INTRODUCTION
Thyroid cancer (TC) is considered the most common malignant neoplasm of the endocrine 
system, accounting for 3.1% of all cancers1-3. Its incidence has soared out considerably in 
the last three decades4-8. Mortality on the other hand, besides being low1, has shown a 
declining trend9,10. The difference observed between incidence and mortality magnitudes 
is possibly due to the higher frequency of the disease occurring in histological types with 
a good prognosis, specifically differentiated thyroid carcinomas (DTC) – which include 
papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC)3,9,11. Although the 
outcome of effective treatment is excellent in the long-term, a small portion of the patients 
present recurrence and some eventually do not respond to conventional therapy, evolving 
to death3,11,12. Identifying potentially aggressive disease cases in advance and evaluating 
the most appropriate treatment strategy for each case has been a challenge.
Prospective randomized controlled trials would be suitable for identifying factors that 
predict prognosis for DTC in the long-term, especially those related to treatment. However, 
the low mortality rate of the disease combined with its prolonged nature and follow-up costs 
make it difficult to conduct these trials. Therefore, there are few studies in the scientific 
literature that explore empirical data on this theme, mainly in Brazilian cohorts, justifying 
observational studies. Thus, the objectives of this study were to estimate the specific 5-year 
survival and to identify the prognostic factors of a hospital cohort of adult patients with DTC.
MATERIAL AND METHODS
Study Design and Population
This retrospective hospital-based cohort study was conducted at the Brazilian National 
Cancer Institute José Alencar Gomes da Silva (INCA), and the outcome variable was 
the time between the diagnosis of primary DTC and the death due to the disease. The 
study population consisted of patients who were attended between January 1st, 2000 and 
December 31, 2010 and registered in the database of the Hospital-based Cancer Registry 
(HBCR). Eligibility was considered as histologically confirmed cases of thyroid carcinoma 
according to the International Classification of Disease for Oncology – Third Edition, site 
codes (C73.0 – 73.9), and who underwent a therapeutic plan and follow-up at INCA (N = 
739); who had a diagnosis at or above 20 years of age (N = 672), and presented the following 
histological codes (N = 620): 8050, 8260, 8340-8344, and 8350 (PTC), and 8290, 8330-8332, 
and 8335 (FTC). 
Cases (N = 51) with a history of other primary tumor or previous TC diagnosis were excluded 
from the study. After reviewing all the histopathological reports, the following cases were 
excluded: PTC recurrence (N = 2); adenocarcinoma no further specification (N = 2); unclear 
diagnostic about primary or metastatic tumor (N = 1); primary pulmonary tumor (N = 1); 
uncertainty about tumor malignancy, adenoma or carcinoma (N = 1). The sample thus 
consisted of 562 cases of primary DTC.
Data Collection
Selected sociodemographic variables, and variables related to the tumor, treatment and 
follow-up were collected from HBCR database. To complete missing data and to update 
follow-up information, the medical records of the patients were evaluated.  
For the cases lost during follow-up period, the surveillance of deaths with their respective 
dates and basic causes was conducted by consulting the database of the Mortality 
Information System (SIM) of the state of Rio de Janeiro. Other public databases were 
consulted (Individual Taxpayer Registration − CPF and Superior Electoral Court − TSE) 
for cases with information unavailable on SIM.
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Covariates of Interest
The variables under study were: sociodemographic (gender and age at diagnosis); tumor 
characteristics (tumor size, stage, histological type, regional lymph node metastasis, and 
distant metastasis); and treatment (type of surgery, unilateral or bilateral, cervical and/or 
mediastinal lymphadenectomy, radioiodine, and radiotherapy). Due to the high percentage 
of lack of information for the clinical staging of the tumor (66.3%), pathological staging 
(pTNM) was used for surgical cases and clinical staging for non-surgical patients (0.5%), 
based on the 7th and 8th editions of the TNM staging system13,14. One of the differences 
between TNM 7th and 8th editions is the change in the age of poor prognosis from 45 to 
55 years. Moreover, the T3 definition has been revised. Finally, there were changes in 
groupings by stages for the age group ≥ 55 years.
Statistical Analysis
Baseline characteristics were reported using measures of central tendency and dispersion 
for continuous variables and proportions for categorical variables. Descriptive data were 
compared across groups using Student’s t-test for continuous variables and Chi-square or 
Fisher’s exact tests for categorical variables. In both tests, the significance level was less 
than 0.05. 
Specific survival was defined as the duration from the date of diagnosis to death due to 
DTC. Survival time was censored for patients alive at the end of the study period, lost during 
follow-up or deceased due to other causes. The Kaplan-Meier method was used to compute 
5-year survival probability and its respective 95% confidence interval (CI). The survival 
curves were plotted to present the differences in the survival of the patients according to 
the effective categorical variables, and survival distributions were compared across groups 
using the log-rank test. Statistical significance was accepted as p < 0.05. 
Multivariate survival analysis and hazard ratio (HR) were calculated using Cox’s model. 
Two models were estimated, considering age grouping of TNM 7th and 8th editions. 
A multivariate model was constructed for each one by adding each of the variables that, 
in a univariate analysis, presented p ≤ 0.20 in Wald’s test, starting from the lowest to the 
highest p-value. At each step, the variables that presented p ≥ 0.10 were excluded. In the 
final model, significant variables were maintained at 5% level – except for gender and age 
at diagnosis, which were kept independent of their statistical significance due to their 
potential for confounding.
For DTC, staging was composed by age at diagnosis and the characteristics related to the 
size of the primary tumor, the regional lymph nodes, and the distant metastasis. Thus, 
instead of the staging itself, it was decided to use its components in a disaggregated way to 
evaluate the effect of each covariate on DTC survival. To compare these covariates, cases 
with missing values were excluded from Cox’s model. The final model was chosen based on 
the likelihood ratio test (ANOVA) at a significance level of 0.05. We looked for interactions.
The overall fit of the model was evaluated by the explanatory power (R2 of the selected 
model/R2 of the saturated model) and concordance probability. The assumption of Cox’s 
proportional hazards model was assessed by the analysis of Schoenfeld residues and the 
impact of outliers was analyzed using martingale, deviance and score residuals. The data 
was analyzed by R software, version 3.4.0, using the Survival package. 
Ethical Aspects
In compliance with the requirements of Resolution 466/2012 and complements of the National 
Board of Health, this study was approved by the Research Ethics Committee of the National 
School of Public Health Sergio Arouca, under protocol CAAE no. 62062116.8.0000.5240 and, 
by INCA Committee, protocol CAAE no. 57282216.8.0000.5274.
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RESULTS
Cohort characteristics
Of the 562 cases of DTC, 79.0% were women, for 3.8 female to male ratio (F/M). The mean 
age at diagnosis was 46.5 years (median age 45 years, ranging from 20 to 91 years). The 
mean primary tumor size, known for 85.9% of cases, was 2.3 cm (median of 1.8 cm, ranging 
from 0.1 to 14.0 cm). Lymph node metastasis, with information for 98.2% of the cohort, and 
distant metastasis were present in 38.8% and 5.3% of the patients, respectively. Most of the 
cases were of staging I (61.2% and 74.8% considering TNM 7th and 8th editions, respectively).
Compared with females, males exhibited a larger mean tumor size (3.2 cm versus 2.1 cm, 
p < 0.001), a lower proportion of microcarcinomas, i.e., tumors ≤ 1.0 cm (21.0% versus 33.1%, 
p = 0.023) and a higher proportion of regional lymph node metastasis (50.9% versus 35.6%, 
p = 0.004). No statistically significant differences were found for age at diagnosis, distant 
metastasis and staging between women and men.
The cohort was composed of 91.3% of cases of PTC. Compared with PTC, FTC showed a 
higher mean age at diagnosis (54.4 years versus 46.0 years, p = 0.015) and higher mean 
tumor size (3.0 cm versus 2.3 cm, p = 0.021). The F/M ratio was 4.1 for PTC and 1.7 for FTC.
Table 1 shows the characteristics of the study population by histological types. FTC 
presented a higher proportion of men and a higher frequency of patients who were positive 
for distant metastasis. In contrast, PTC showed a higher proportion of cases with regional 
lymph node metastasis and a higher frequency of microcarcinomas. The distribution of 
staging differed between histological types, while PTC presented a higher proportion of 
staging I, FTC exhibited higher frequencies of stages II, III and IVC (TNM 7th edition) or II, 
III and IVB (TNM 8th edition).
Multifocal lesions were only observed for PTC (10.7%). The most commonly observed PTC 
variants were classical (25.3%) and follicular (17.7%) variants, but no histological subtype 
specification was found for 53.8% of the cases. For FTC, 36.7% of the patients who had the 
variant information belonged to the Hürthle cell subtype.
Follow-up
During the 5-year follow-up, 539 censures and 23 deaths related to TC were observed. 
Censored group consisted of 522 living individuals at the end of 60 months, 14 deaths 
from other causes and 3 follow-up losses (0.5%), which were female, PTC, stages I, III and 
IVA (TNM 7th edition) or I, II, III  (TNM 8th edition) and follow-up times of 34.5, 8.2 and 
6.7 months, respectively. Moreover, they were older (mean age 66.3 years versus 46.4 years, 
p = 0.018) when compared to complete follow-up cases. The mean follow-up time of the 
cohort was 57.5 months, being 58.9 months for the censored cases and 23.4 months for 
those who suffered the outcome.
Deaths related to Differentiated Thyroid Cancer
Of the 23 deaths observed, 91.3% were aged ≥ 45 years (TNM 7th edition) or 87.0% were aged 
≥ 55 years (TNM 8th edition) and 56.5% had distant metastasis (Table 2). All patients with 
FTC who died had distant metastasis. Among PTC deaths, the proportion of patients with 
distant metastasis was 47.4%. Compared with PTC, FTC deaths had smaller tumors (mean 
size 2.3 cm versus 4.2 cm, p = 0.014) and higher mean age at diagnosis (72.5 years versus 
65.4 years), with no significant difference. In both histological types, 50% of the deaths had 
regional lymph node metastasis.
Survival
Figure 1 presents the 5-year specific survival probability of DTC, which was 95.8% 
(95%CI: 94.2–97.5). 
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Table 1. Sociodemographics and clinical characteristics of patients diagnosed with thyroid cancer by 
histological type, Brazil, 2000-2015.
Variablesa
Histological types
p valuebPapillary Follicular
N % N %
Gender
Male 100 19.5 18 36.7 0.008
Female 413 80.5 31 63.3
Total 513 100 49 100
Age at diagnosis − TNM 7th edition
20-44 251 48.9 14 28.6 0.010
≥ 45 262 51.1 35 71.4
Total 513 100 49 100
Age at diagnosis − TNM 8th edition
20-54 385 75.0 29 59.2 0.025
≥ 55 128 25.0 20 40.8
Total 513 100 49 100
Staging − TNM 7th edition
I 320 63.7 17 34.7 < 0.001
II 43 8.6 6 12.2
III 59 11.8 13 26.5
IVA 61 12.2 6 12.2
IVB 3 0.6 − −
IVC 16 3.2 7 14.3
Total 502 100 49 100
Staging − TNM 8th edition
I 387 77.1 25 51.0 < 0.001
II 66 13.1 13 26.5
III 30 6.0 4 8.2
IVA 3 0.6 − −
IVB 16 3.2 7 14.3
Total 502 100 49 100
Tumor size
< 4.0 cm 367 82.3 27 73.0 0.237
≥ 4.0 cm 79 17.7 10 27.0
Total 446 100 37 100
Microcarcinoma
No 303 67.9 33 89.2 0.005
Yes 143 32.1 4 10.8
Total 446 100 37 100
Regional lymph nodes metastasis
No 294 58.4 44 89.8 < 0.001
Yes 209 41.6 5 10.2
Total 503 100 49 100
Distant metastasis
No 491 95.7 41 83.7 0.003
Yes 22 4.3 8 16.3
Total 513 100 49 100
a Missings: staging (N = 11; 1.8%), tumor size (N = 79; 14.1%), regional lymph nodes metastasis (N = 10, 1.8%) e 
microcarcinoma (N = 79; 14.1%).
b p value of Chi-square or Fisher’s exact tests, being in bold when p < 0.05.
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Table 2 and Figure 2 present, respectively, the 5-year conditional survival probability and 
the Kaplan-Meier curves according to sociodemographic and clinical variables. Women 
showed greater survival (97.0%; 95%CI: 95.5 – 98.6) than men (91.5%; 95%CI: 86.6 – 96.7). 
A similar scenario occurred with individuals diagnosed in the age group of 20–44 years 
(99.2%; 95%CI: 98.2 – 100) compared to those aged ≥ 45 years (92.8%, 95%CI: 89.9 – 95.8), and 
with age group of 20-54 years (99.3%; 95%CI: 98.5 – 100) compared to those aged ≥ 55 years 
(85.9%; 95%CI: 80.4 – 91.9). There was a greater probability of survival for tumors smaller 
than 4.0 cm (97.4%; 95%CI: 95.9 – 99.0) than for those ≥ 4.0 cm (87.1%, 95%CI: 80.3 – 94.5). 
The positive individuals for distant metastasis had worse survival (54.8%; 95%CI: 39.2 – 76.4) 
than those negative (98.1%; 95%CI: 96.9 – 99.3). Considering TNM 7th edition, stages I/II, 
III and IVA/IVB presented survival probabilities higher than 90.0%. On the other hand, 
the survival of the IVC stage was 47.1% (95%CI: 30.4 – 73.0). By the TNM 8th edition, for 
stages I/II, III/IVA and IVB the survival probabilities were 98.6% (95%CI: 97.5 – 99.6), 87.3% 
(95%CI: 76.4 – 99.7) and 47.1% (95%CI: 30.4 – 73.0), respectively.
Although FTC showed lower survival (91.8%; 95%CI: 84.5 – 99.8) than PTC (96.2%; 
95%CI: 94.6 – 97.9), no statistically significant difference between the estimated curves 
was observed (p = 0.139). Moreover, no significant differences were observed in the survival 
curves estimated according to the variables microcarcinoma, multifocal lesions and regional 
lymph nodes metastasis.
In total, 99.5% of the patients underwent surgery, 96.2% underwent total thyroidectomy 
and 3.8% subtotal thyroidectomy. Only three cases (0.5%) did not undergo any surgical 
intervention because the tumors were considered non-resectable. Thus, excluding these 
three cases from the analysis, no statistically significant difference was observed between 
total thyroidectomy and subtotal thyroidectomy survival curves.
Cases that underwent lymphadenectomy had lower survival (93.2%, 95%CI: 89.5 – 97.0) than 
those who did not undergo this type of intervention (97.1%, 95%CI: 95.4 – 98.8). Patients 
who received adjuvant radioiodine therapy had better survival (97.7%; 95%CI: 96.3 – 99.1) 
when compared to those who did not receive this treatment (88.8%; 95%CI: 83.2 – 94.7). 
Compared with cases treated with radiotherapy (70.5%, 95%CI: 54.3 – 91.6), other cases had 
better survival (97.0%, 95%CI: 95.5 – 98.4) (Table 2 and Figure 2).
Prognostic factors
For both analyses – considering the age grouping of TNM 7th and 8th editions – the most 
appropriate multivariate model was one in which the effects of covariables age, distant 
Figure 1. Kaplan-Meier plot of 5-year specific survival in differentiated thyroid cancer patients.
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Table 2. Conditional 5-year survival probability estimated by Kaplan-Meier, mean survival time according 
to sociodemographic, tumor characteristics and treatment for patients with differentiated thyroid cancer.
Variablesa
Cases Deaths
Conditional 5-year 
survival probabilities Log-rankd
Mean 
survival 
timeeN % N % S(t)b 95% CIc
Gender
Male 118 21.0 10 43.5 91.5 86.6 – 96.7
0.009
57.5
Female 444 79.0 13 56.5 97.0 95.5 – 98.6 57.5
Total 562 100 23 100
Age at diagnosis − TNM 7th edition
20-44 265 47.2 2 8.7 99.2 98.2 − 100
< 0.001
59.1
≥ 45 297 52.8 21 91.3 92.8 89.8 – 95.8 56.0
Total 562 100 23 100
Age at diagnosis − TNM 8th edition
20-54 414 73.7 3 13.0 99.3 98.5 − 100
< 0.001
59.1
≥ 55 148 26.3 20 87.0 85.9 80.4 − 91.9 52.8
Total 562 100 23 100
Staging − TNM 7th edition
I/II 386 70.1 2 8.7 99.5 98.8 − 100
< 0.001
59.1
III 72 13.1 3 13.0 95.8 91.2 − 100 57.4
IVA/IVB 70 12.7 6 26.1 90.8 84.0 – 98.1 53.7
IVC 23 4.2 12 52.2 47.1 30.4 – 73.0 39.8
Total 551 100 23 100
Staging − TNM 8th edition
I/II 491 89.1 7 30.4 98.6 97.5 – 99.6
< 0.001
58.8
III/ IVA 37 6.7 4 17.4 87.3 76.4 – 99.7 50.0
IVB 23 4.2 12 52.2 47.1 30.4 – 73.0 39.8
Total 551 100 23 100
Tumor size
< 4.0 cm 394 81.6 10 47.6 97.4 95.9 – 99.0
< 0.001
58.1
≥ 4.0 cm 89 18.4 11 52.4 87.1 80.3 – 94.5 54.1
Total 483 100 21 100
Distant metastasis
No 532 94.7 10 43.5 98.1 96.9 – 99.3 
< 0.001
58.4
Yes 30 5.3 13 56.5 54.8 39.2 – 76.4 40.7
Total 562 100 23 100
Lymphadenectomy
No 381 67.8 11 47.8 97.1 95.4 – 98.8
0.031
58.3
Yes 181 32.2 12 52.2 93.2 89.5 – 97.0 55.8
Total 562 100 23 100
Radioiodine therapy
No 122 21.7 13 56.5 88.8 83.2 – 94.7
< 0.001
53.1
Yes 440 78.3 10 43.5 97.7 96.3 – 99.1 58.7
Total 562 100 23 100
Radiotherapy
No 536 95.4 16 69.6 97.0 95.5 – 98.4
< 0.001
58.0
Yes 26 4.6 7 30.4 70.5 54.3 – 91.6 46.0
Total 562 100 23 100
a Missings: staging (N = 11; 2.0%) and tumor size (N = 79; 14.1%).
b Conditional 5-year survival probabilities.
c 95% confidence interval.
d p value of log-rank test, being in bold when p < 0.05.
e Mean survival time in months.
There were no statistically significant differences between the survival curves of histological type, 
microcarcinoma, multifocal lesions and regional lymph node metastasis.
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metastasis, lymphadenectomy, and radioiodine therapy were controlled by baseline risk 
variation attributable to covariant sex strata (Cox’s model stratified by sex) present in 
Table 3. Considering the age grouping of TNM 7th edition, cases diagnosed in the age group 
≥ 45 years had 9.88 times greater risk of death from TC than those aged 20-44 years (95%CI: 
1.67 – 58.33); the positive patients for distant metastasis showed 18.87 (95%CI: 7.38 – 48.29) 
higher risk of dying than the negative cases; the individuals submitted to lymphadenectomy 
presented 6.36 (95%CI: 2.26 – 17.91) higher risk of death than those who had no indication 
for this surgical intervention; and the cases of TC that received radioiodine therapy had a 
84.0% lower risk of death than those who did not have a recommendation for this therapeutic 
modality (adjusted HR: 0.16; 95%CI: 0.06 – 0.43). Considering the age grouping of TNM 8th 
edition, the risk estimates were 10.12 (95%CI: 2.05 – 50.09) for age group ≥ 55 years, 12.43 
(95%CI: 4.58 – 33.77) for positive individuals with distant metastasis, 5.06 (95%CI: 1.82 – 
14.05) for patients underwent to lymphadenectomy and 0.19 (95%CI: 0.07 – 0.51) for those 
who received radioiodine therapy.  
Schoenfeld’s residues showed that the premise of proportional hazards was not violated 
(p = 0.132 and 0.329 for models considering age grouping of TNM 7th and 8th editions, 
respectively). Considering the age grouping of TNM 7th edition, the final model explained 
39.2% of the data variability and the probability of agreement was 95.9%. For the 8th edition, 
they were 39.7% and 95.2%, respectively. No interaction was observed between the variables. 
Figure 2. Kaplan-Meier plot of 5-year specific survival in differentiated thyroid cancer patients by sociodemographic, treatment and tumor-
related covariates. 
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Using the martingale and deviance residues, for multivariate model considering the age 
grouping of TNM 7th edition, three outliers were identified: a woman who died in a very 
short time (3.0 months), even though she was 38 years old, PTC and stage I; a 72-year-old 
woman with PTC and IVA staging (tumor size = 7.0 cm) who died at 23.3 months; and a 
75-year-old woman with PTC and IVA staging (tumor size = 2.0 cm) who had the outcome 
at 11.8 months. For final model considering age grouping TNM 8th edition, three outliers 
also were identified: the first two described previously and a 51-year-old woman with PTC 
and IVB staging with outcome at 36.1 months. No influential points were observed by 
scoring residue analysis.
DISCUSSION
The results of this study pointed out a higher 5-year survival rate for patients with 
DTC. For either both sexes, diagnostic age, distant metastasis, lymphadenectomy and 
radioiodine therapy were shown to be important independent prognostic factors. Despite 
the differences found in conditional survival probabilities between sex, age, tumor size, 
Table 3. Crude and adjusted Hazard Ratios for differentiated thyroid cancer patients, using the Cox model.
Variables Crude HRa 95%CIb p valuec
Multivariate model using age grouping 
of the TNM 7th edition
Multivariate model using age grouping 
of the TNM 8th edition
adjusted 
HRa
95%CIb p valuec
adjusted 
HRa
95%CIb p valuec
Gender
Female 1.00
Multivariate Cox model stratified by gender
Male 2.75 1.16 – 6.52 0.022
Age at diagnosis – TNM 7th edition
20-44 1.00 1.00 - - -
≥ 45 8.68 2.02 – 37.27 0.004 9.88 1.67 – 58.33 0.011 - - -
Age at diagnosis – TNM 8th edition
20-54 1.00 - - - 1.00
≥ 55 17.60 5.18 – 59.76 < 0.001 - - - 10.12 2.05 – 50.09 0.005
Distant metastasis
No 1.00 1.00 1.00
Yes 28.61 12.08 – 67.77 < 0.001 18.87 7.38 – 48.29 < 0.001 12.43 4.58 – 33.77 < 0.001
Radioiodine therapy
No 1.00 1.00 1.00
Yes 0.22 0.09 – 0.52 0.001 0.16 0.06 – 0.43 < 0.001 0.19 0.07 – 0.51 0.001
Lymphadenectomy
No 1.00 1.00 1.00
Yes 2.57 1.10 – 6.02 0.035 6.36 2.26 – 17.91 0.001 5.06 1.82 – 14.05 0.002
Tumor size
< 4.0 cm 1.00 - - - - - -
≥ 4.0 cm 5.18 2.20 – 12.2 < 0.001 - - - - - -
Microcarcinoma
Yes 1.00 - - - - - -
No 2.71 0.80 – 9.20 0.110 - - - - - -
Radiotherapy
No 1.00
Yes 8.96 3.47 – 23.13 < 0.001
a Hazard Ratio; b CI= confidence interval; c Wald’s test p value, being in bold when p < 0.05.
Histological type and regional lymph nodes metastasis variables presented p > 0.20 in univariate Cox model.
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lymphadenectomy and radioiodine categories, estimates were also favorable for each 
stratum, with magnitudes ranging from 87.0% to 99.5%.
The greatest differences in survival were observed for patients with distant metastasis 
and for cases submitted to radiotherapy. As expected, individuals with IVC (TNM 7th 
edition) or IVB (TNM 8th edition) staging also had much lower survival. Thus, age ≥ 45 years 
(TNM 7th edition), age ≥ 55 years (TNM 8th edition), presence of distant metastasis and 
lymphadenectomy were considered as factors that negatively influenced the prognosis. 
On the other hand, radioiodine therapy was considered a protection factor.
Survival analysis has often been used to evaluate prognostic factors related to the patient 
and tumor, as well as to the efficacy of the treatments recommended for cancer. However, for 
DTC this evaluation is particularly difficult because of the low disease-related mortality rate. 
In this study, the probability of dying as a result of TC was 4.2% in 5 years. Mazzaferi et al.14 
observed death probability at 4.0%, 6.0% and 8.0% at 10, 20, and 30 years, respectively, in a 
cohort of patients with DTC in the United States. Since their cohort was younger (mean age 
was 35.7 years), it could be a possible explanation for the observation of lower probability 
of death in the long-term.
As mentioned, the age ranges (< 45 years and ≥ 45 years) used by TNM 7th edition13 was 
appropriate to predict death in the present study. However, the age ranges (< 55 years and 
≥ 55 years) used by TNM 8th edition14 seems to be better to stratify the risk of death. In fact, 
the patient’s age has been described in the literature15,16-18 as a relevant prognostic factor of 
death. The classic cut-off point was not observed in two hospital-based studies conducted 
in the United States16-18. Age above 50 years was described as an independent prognostic 
factor associated with death by DTC16. For PTC, another American study18 stratified age 
in three age groups (< 45 years, 45-60 years and > 60 years), using < 45 years as a reference 
category. This study showed an adjusted HR of 73.61 and 25.50 for the age groups of 45-60 
and > 60 years, respectively. The possibility of death due to other causes before dying by TC 
was attributed for the reduced risk in those aged > 60 years. 
Some studies argue that sex is a factor associated with death by TC15,17. Mazzaferi et al.15 
evaluated the prognostic factors of DTC excluding cases with distant metastasis, and 
reported that women had a 50% lower risk of dying than men. McConahey el at.17 reported 
that, for PTC, male sex was highly associated with death. In contrast, sex did not influence 
the prognosis of PTC according Grogan et al.18. In our study, males presented a higher risk of 
death in the univariate analysis. However, the effect of this covariate could not be estimated 
in the multivariate analysis since it was observed that the baseline risk was not equal for 
women and men. To solve this non-proportionality, the survival modeling process was 
performed considering that sex divided the cohort into two strata with different baselines, 
and the effects of the other covariates being controlled by the variation in baseline risk 
attributable to men and women.
Our results – as well as in other studies18,19 – suggest that distant metastasis is an important 
prognostic factor for DTC. The estimates of death risk were very high, both in the univariate 
and in the multivariate analyses, whereas regional lymph node metastasis was not 
identified as a prognostic factor. In fact, few studies18,19 have considered that regional lymph 
node metastasis influences the survival of TC despite seeming to have a role in disease 
recurrence15,18-23. Although metastasis to regional lymph nodes did not impact the outcome, 
lymphadenectomy was surprisingly associated with increased risk of death. Perhaps the 
differences in the extent of lymphadenectomy may better explain these findings, and more 
information is needed to clarify them.
The benefits of radioiodine therapy for ablation of remaining thyroid tissue are 
controversial, especially in the early stages of the disease. For our study population, 
postoperative radioiodine therapy significantly improved DTC survival. Similarly, in the 
study of Mazzaferi et al.15, radioiodine therapy was a protective factor for differentiated 
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non-metastatic carcinomas. For Jonklaas et al.24, a better specific survival was associated 
only in stages III and IV of radioiodine therapy. A similar finding was found by Carhill et al.25 
in evaluating overall survival. However, Grogan et al.18 found no statistically significant 
association for PTC. Given the contradictory evidence in the literature, this therapy should 
not be used indiscriminately, especially in low risk patients18 given the highest risk of a 
second primary cancer26,27.
Tumor size (≥ 4.0 cm) and radiotherapy negatively influenced the outcome only in the 
univariate analysis. Contrary to what has been described in the literature15,18,28-30, in the 
present study, the DTC cohort survival did not differ according to the microcarcinoma, 
multifocal lesions and histological type (possibly due to the small proportion of FTC 
patients). Unfortunately, the risk of death related to the extension of surgery could not be 
evaluated in this study, since the proportion of cases submitted to subtotal thyroidectomy 
was very small.
Estimated survival from HBCR data tend to be higher than population-based cancer 
registries. Moreover, differences in eligibility criteria, outcome definition, classification of 
covariates, methods used to estimate survival and identify prognostic factors may interfere 
in the results obtained. The diagnostic criteria was changed in 198831, and many cancers 
previously classified as follicular have come to be categorized as a follicular variant of 
papillary carcinoma, thus causing an increase in the proportion of PTC. Thus, studies that 
used data prior to this modification may have reached different conclusions.
Limitations of this study include retrospective data collection. However, conducting a 
prospective study to evaluate TC is very difficult due to the high survival rate of the disease. 
Because of few events, the low statistical accuracy makes the results hard to interpret. 
Furthermore, as this study covered a decade of data, some variation in the treatment 
may have occurred, making it difficult to compare the therapeutic protocols. Advances in 
diagnostic technologies have reduced the number of cases with tumor invasion to adjacent 
thyroid structures. Only three patients with non-resectable tumors were observed, and 
comparisons within this group were not possible. The lack of standard information in the 
histopathological reports made the evaluation of the subtypes of PTC and FTC impossible.
A very high survival over a 5-year period was found in this study. The prognosis was 
negatively influenced by age, distant metastasis and lymphadenectomy, whereas radioiodine 
therapy was found to be protective. When compared to TNM 7th edition, the 8th edition age 
ranges seems to be better to predict death in the present study. 
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: 
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 
CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492 
2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, et al. International patterns and 
trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control. 2009;20(5):525-31. 
https://doi.org/10.1007/S10552-008-9260-4 
3. Ron E, Schneider AB. Thyroid cancer. In: Schottenfeld D, Fraumeni JF, editors. Cancer 
epidemiology and prevention. 3. ed. New York: Oxford University Press; 2006. p. 975-94.
4. Akslen LA, Haldorsen T, Thoresen SO, Glattre E. Incidence pattern of thyroid cancer 
in Norway: influence of birth cohort and time period. Int J Cancer. 1993;53(9):183-7. 
https://doi.org/ 10.1002/ijc.2910530202
5. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. 
JAMA. 2006;295(18):2164-7. https://doi.org/10.1001/jama.295.18.2164 
6. Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 
1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335-9. 
https://doi.org/10.1054/bjoc.2001.2061 
12
Thyroid carcinoma survival study Borges AKM et al.
https://doi.org/10.11606/S1518-8787.2019053001496
7. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence 
of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 
2013;2013:965212. https://doi.org/10.1155/2013/965212 
8. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact of 
diagnostic changes on the rise in thyroid cancer incidence: a population-based study in selected 
high-resource countries. Thyroid. 2015;25(10):1127-36. https://doi.org/10.1089/thy.2015.0116 
9. La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi 
F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 
2015;136(9):2187-95https://doi.org/10.1002/ijc.29251 
10. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, et al. Cancer mortality in 
Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol. 2010;2(6)1:1323-60. 
https://doi.org/10.1093/annonc/mdp530
11. Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard BA, et al. Guidelines for 
the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122. 
https://doi.org/10.1111/cen.12515 
12. Rosário PW, Ward LS, Carvalho GA, Graf H, Maciel RMB, Maciel LMZ, et al. Nódulo tireoidiano 
e câncer diferenciado de tireoide: atualização do consenso brasileiro. Arq Bras Endocrinol 
Metab. 2013;57(4):240-64. https://doi.org/10.1590/S0004-27302013000400002
13. Sobin LH, Gospodarowicz M, Wittekind C. TNM: classificação de tumores malignos. 7. ed. Rio 
de Janeiro: INCA; 2012. Glândula tireoide (CID-O C73);. p. 60-4. 
14. Brierley J, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 8. ed. 
Chichester: John Wiley & Sons; 2017. Thyroid Gland (ICD-O-3 C73.9); p. 51-4.
15. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical 
therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28. 
https://doi.org/10.1016/0002-9343(94)90321-2 
16. Brennan MD, Bergstralh EJ, Heerden JA, McConahey WM. Follicular thyroid cancer treated at 
the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and 
outcome. Mayo Clin Proc. 1991;66(1):11-22. https://doi.org/10.1016/S0025-6196(12)61170-7 
17. McConahey WM, Hay ID, Woolner LB, Heerden JA, Taylor WF. Papillary thyroid cancer treated 
at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and 
outcome. Mayo Clin Proc. 1986;61:978-96. https://doi.org/10.1016/S0025-6196(12)62641-X
18. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon CA, et al. A study of recurrence 
and death from papillary thyroid cancer with 27 years of median follow-up. Surgery. 
2013;154(6):1436-47. https://doi.org/10.1016/j.surg.2013.07.008
19. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for 
differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 
2006;106:524-31. https://doi.org/10.1002/cncr.21653 
20. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) 
staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.  
J Clin Endocrinol Metab. 1997;82(11):3553-62. https://doi.org/10.1210/jcem.82.11.4373
21. D’Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan 
FS, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer. 2004;100(6):1123-9. 
https://doi.org/10.1002/cncr.20081 
22. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic 
significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the 
size and number of metastatic lymph nodes, as well as the presence of extranodal extension. 
Thyroid. 2012;22(11):1144-52. https://doi.org/10.1089/thy.2012.0043 
23. Schneider DF, Mazeh H, Chen H, Sippel RS. Lymph node ratio predicts 
recurrence in papillary thyroid cancer. Oncologist. 2013;18(2):157-62. 
https://doi.org/10.1634/theoncologist.2012-0240 
24. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with 
differentiated thyroid carcinoma following initial therapy. Thyroid. 2006;16(12):1229-42. 
https://doi.org/10.1089/thy.2006.16.1229 
25. Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, et al. Long-term outcomes 
following therapy in differentiated thyroid carcinoma: NTCTCS Registry Analysis 1987-2012.  
J Clin Endocrinol Metab. 2015;100(9):3270-9. https://doi.org/10.1210/JC.2015-1346 
13
Thyroid carcinoma survival study Borges AKM et al.
https://doi.org/10.11606/S1518-8787.2019053001496
26. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary 
malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and 
meta-analysis. Thyroid. 2009;19(5):451-7. https://doi.org/10.1089/thy.2008.0392 
27. Rubino C, Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second 
primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638-44. 
https://doi.org/10.1038/sj.bjc.6601319 
28. Sugitani I, Fujimoto Y. Symptomatic versus asymptomatic papillary thyroid microcarcinoma:  
a retrospective analysis of surgical outcome and prognostic factors. Endocr J. 1999;46(1):209-16. 
https://doi.org/10.1507/endocrj.46.209 
29. Dideban S, Abdollahi A, Meysamie A, Sedghi S, Shahriari M. Thyroid papillary microcarcinoma: 
etiology, clinical manifestations, diagnosis, follow-up, histopathology and prognosis. Iran J 
Pathol. 2016;11(1):1-19. 
30. Görges R. The changing epidemiology of thyroid cancer. In: Biersack HJ, Grünwald F, editors. 
Thyroid cancer. Berlin: Springer; 2005. p. 3-27.
31. Hedinger C, Williams ED, Sobin LH. The WHO histological classification of 
thyroid tumors: a commentary on the second edition. Cancer. 1989;63(5):908-11. 
https://doi.org/0.1002/1097-0142(19890301)63:5<908::aid-cncr2820630520>3.0.co;2-i
This investigation did not receive specific funding.
Authors’ Contribution: Design and planning of the study: AKMB, RJK, SK. Data collection, analysis and 
interpretation: AKMB, JDF. Drafting or revision of the manuscript: AKMB, JDF, RJK. Approval of the final version: 
AKMB, JDF, RJK. Public responsability for the contents of the article: AKMB, JDF, SK, RJK.
Conflict of Interests: The authors declare no conflict of interest.
